APA

Garcia M., Romaguera J. E., Inamdar K. V., Rassidakis G. Z. & Medeiros L. J. (20090423). Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. : Cancer.

Chicago

Garcia Mar, Romaguera Jorge E, Inamdar Kedar V, Rassidakis George Z and Medeiros L Jeffrey. 20090423. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. : Cancer.

Harvard

Garcia M., Romaguera J. E., Inamdar K. V., Rassidakis G. Z. and Medeiros L. J. (20090423). Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. : Cancer.

MLA

Garcia Mar, Romaguera Jorge E, Inamdar Kedar V, Rassidakis George Z and Medeiros L Jeffrey. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. : Cancer. 20090423.